Přehled o publikaci
2024
TP53-related clonal competition and disrupted molecular processes in CLL
TAUŠOVÁ, Kristýna; Jakub Paweł PORC; Petr TAUŠ; Karol PÁL; Jitka MALČÍKOVÁ et al.Basic information
Original name
TP53-related clonal competition and disrupted molecular processes in CLL
Authors
TAUŠOVÁ, Kristýna; Jakub Paweł PORC; Petr TAUŠ; Karol PÁL; Jitka MALČÍKOVÁ; Šárka PAVLOVÁ; Kamila STRÁNSKÁ; Marcela ŽENATOVÁ; Boris TICHÝ; Anna PANOVSKÁ; Michael DOUBEK; Šárka POSPÍŠILOVÁ and Karla PLEVOVÁ
Edition
New frontiers in CLL research, Barcelona, 2024
Other information
Language
English
Type of outcome
Konferenční abstrakta
Country of publisher
Spain
Confidentiality degree
is not subject to a state or trade secret
References:
Marked to be transferred to RIV
Yes
RIV identification code
RIV/00216224:14740/24:00137827
Organization
Středoevropský technologický institut – Repository – Repository
Keywords in English
CLL; T53 gene; mutations
Links
MUNI/A/1558/2023, interní kód Repo. NW24-03-00114, research and development project.
Changed: 23/12/2025 00:51, RNDr. Daniel Jakubík
Abstract
In the original language
The presence of either TP53 gene loss or mutation defined high-risk CLL especially in the era of chemoimmunotherapy. Its prognostic and predictive impact remains a matter of debate in the setting of BTKi- and BCL2i-based treatment, which does not act directly via the TP53 pathway, but yet seems to associate with worse clinical outcomes. The adverse effect on overall survival, at least upon chemoimmunotherapy, is notable not only in patients with expanded but also in lowburden TP53 mutations, which were identified in 5–35% of CLL patients. In this study, we aimed to scrutinize the principles of clonal competition in CLL and identify factors influencing the development of TP53-mutated subclones in various clinical contexts.
